APO Research
Talk to an analyst

APO RESEARCH · REPORT

Post-Traumatic Stress Disorder (PTSD) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Analysis and Forecast 2026-2032

20 December 2025195 pages

Choose your research edition.

Industry ResearchPost-Traumatic Stress Disorder (PTSD) Therapeutics Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal Post-Traumatic Stress Disorder (PTSD) Therapeutics Industry Growth and Trends Forecast to 203261 pages · $3,450 USDMarket StructureGlobal Post-Traumatic Stress Disorder (PTSD) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032171 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Post-Traumatic Stress Disorder (PTSD) Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Post-Traumatic Stress Disorder (PTSD) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Post-Traumatic Stress Disorder (PTSD) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Post-Traumatic Stress Disorder (PTSD) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Post-Traumatic Stress Disorder (PTSD) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Post-Traumatic Stress Disorder (PTSD) Therapeutics include Eli Lilly, Pfizer, GlaxoSmithKline and H. Lundbeck, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Post-Traumatic Stress Disorder (PTSD) Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Post-Traumatic Stress Disorder (PTSD) Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Post-Traumatic Stress Disorder (PTSD) Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Post-Traumatic Stress Disorder (PTSD) Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Post-Traumatic Stress Disorder (PTSD) Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Post-Traumatic Stress Disorder (PTSD) Therapeutics Segment by Company

Eli Lilly

Pfizer

GlaxoSmithKline

H. Lundbeck

Post-Traumatic Stress Disorder (PTSD) Therapeutics Segment by Type

Antidepressants

Anxiolytics

Post-Traumatic Stress Disorder (PTSD) Therapeutics Segment by Application

Hospital

Pharmacy

Other

Post-Traumatic Stress Disorder (PTSD) Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Post-Traumatic Stress Disorder (PTSD) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Post-Traumatic Stress Disorder (PTSD) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Post-Traumatic Stress Disorder (PTSD) Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Post-Traumatic Stress Disorder (PTSD) Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Post-Traumatic Stress Disorder (PTSD) Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Antidepressants Major Player Table 3. Anxiolytics Major Player Table 4. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Pharmacy Major Player Table 7. Other Major Player Table 8. Post-Traumatic Stress Disorder (PTSD) Therapeutics Industry Trends Table 9. Post-Traumatic Stress Disorder (PTSD) Therapeutics Industry Drivers Table 10. Post-Traumatic Stress Disorder (PTSD) Therapeutics Industry Opportunities and Challenges Table 11. Post-Traumatic Stress Disorder (PTSD) Therapeutics Industry Restraints Table 12. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Share by Region (2021-2026) Table 15. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Share by Region (2027-2032) Table 17. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Market Share by Players (2021-2026) Table 19. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Key Players Headquarters & Area Served Table 21. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Players, Product Type & Application Table 22. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Market Share by Type (2021-2026) Table 29. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Market Share by Type (2027-2032) Table 30. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Market Share by Application (2021-2026) Table 34. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Market Share by Application (2027-2032) Table 35. Eli Lilly Company Information Table 36. Eli Lilly Business Overview Table 37. Eli Lilly Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Eli Lilly Post-Traumatic Stress Disorder (PTSD) Therapeutics Product Portfolio Table 39. Eli Lilly Recent Development Table 40. Pfizer Company Information Table 41. Pfizer Business Overview Table 42. Pfizer Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Pfizer Post-Traumatic Stress Disorder (PTSD) Therapeutics Product Portfolio Table 44. Pfizer Recent Development Table 45. GlaxoSmithKline Company Information Table 46. GlaxoSmithKline Business Overview Table 47. GlaxoSmithKline Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. GlaxoSmithKline Post-Traumatic Stress Disorder (PTSD) Therapeutics Product Portfolio Table 49. GlaxoSmithKline Recent Development Table 50. H. Lundbeck Company Information Table 51. H. Lundbeck Business Overview Table 52. H. Lundbeck Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. H. Lundbeck Post-Traumatic Stress Disorder (PTSD) Therapeutics Product Portfolio Table 54. H. Lundbeck Recent Development Table 55. North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 56. North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 57. North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 58. North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 59. North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 60. North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 61. North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 62. Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 63. Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 64. Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 65. Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 66. Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 67. Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 68. Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 69. China Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 70. China Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 71. China Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 72. China Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 73. Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 74. Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 75. Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 76. Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 77. Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 78. Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 79. Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 80. SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 81. SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 82. SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 83. SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 84. SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 85. SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 86. SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Post-Traumatic Stress Disorder (PTSD) Therapeutics Image Figure 2. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Antidepressants Image Figure 5. Anxiolytics Image Figure 6. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Pharmacy Image Figure 10. Other Image Figure 11. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size (US$ Million) & (2021-2032) Figure 12. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Market Share by Type (2021-2032) Figure 19. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Market Share by Application (2021-2032) Figure 22. North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Type (2021-2032) Figure 24. North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Application (2021-2032) Figure 25. North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Country (2021-2032) Figure 26. United States Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Type (2021-2032) Figure 31. Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Application (2021-2032) Figure 32. Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Country (2021-2032) Figure 33. Germany Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Type (2021-2032) Figure 43. China Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Application (2021-2032) Figure 44. Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Type (2021-2032) Figure 46. Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Application (2021-2032) Figure 47. Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Region (2021-2032) Figure 48. Japan Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Type (2021-2032) Figure 56. SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Application (2021-2032) Figure 57. SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Country (2021-2032) Figure 58. Brazil Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Antidepressants
  • Anxiolytics
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • H. Lundbeck

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Post-Traumatic Stress Disorder (PTSD) Therapeutics Market by Type
  3. 1.2.1 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Antidepressants
  5. 1.2.3 Anxiolytics
  6. 1.3 Post-Traumatic Stress Disorder (PTSD) Therapeutics Market by Application
  7. 1.3.1 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Pharmacy
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Dynamics
  1. 2.1 Post-Traumatic Stress Disorder (PTSD) Therapeutics Industry Trends
  2. 2.2 Post-Traumatic Stress Disorder (PTSD) Therapeutics Industry Drivers
  3. 2.3 Post-Traumatic Stress Disorder (PTSD) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Post-Traumatic Stress Disorder (PTSD) Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Growth Trends by Region
  3. 3.2.1 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Players
  2. 4.1.1 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Players, Product Type & Application
  8. 4.5 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Post-Traumatic Stress Disorder (PTSD) Therapeutics Tier 1, Tier 2, and Tier 3
5 Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size by Type
  1. 5.1 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Market Share by Type (2021-2032)
6 Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size by Application
  1. 6.1 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Eli Lilly
  2. 7.1.1 Eli Lilly Company Information
  3. 7.1.2 Eli Lilly Business Overview
  4. 7.1.3 Eli Lilly Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Eli Lilly Post-Traumatic Stress Disorder (PTSD) Therapeutics Product Portfolio
  6. 7.1.5 Eli Lilly Recent Developments
  7. 7.2 Pfizer
  8. 7.2.1 Pfizer Company Information
  9. 7.2.2 Pfizer Business Overview
  10. 7.2.3 Pfizer Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Pfizer Post-Traumatic Stress Disorder (PTSD) Therapeutics Product Portfolio
  12. 7.2.5 Pfizer Recent Developments
  13. 7.3 GlaxoSmithKline
  14. 7.3.1 GlaxoSmithKline Company Information
  15. 7.3.2 GlaxoSmithKline Business Overview
  16. 7.3.3 GlaxoSmithKline Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 GlaxoSmithKline Post-Traumatic Stress Disorder (PTSD) Therapeutics Product Portfolio
  18. 7.3.5 GlaxoSmithKline Recent Developments
  19. 7.4 H. Lundbeck
  20. 7.4.1 H. Lundbeck Company Information
  21. 7.4.2 H. Lundbeck Business Overview
  22. 7.4.3 H. Lundbeck Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 H. Lundbeck Post-Traumatic Stress Disorder (PTSD) Therapeutics Product Portfolio
  24. 7.4.5 H. Lundbeck Recent Developments
8 North America
  1. 8.1 North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue (2021-2032)
  2. 8.2 North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country
  11. 8.6.1 North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country
  11. 9.6.1 Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue (2021-2032)
  2. 10.2 China Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country
  11. 11.6.1 Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Post-Traumatic Stress Disorder (PTSD) Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst